구조모아 (StructureMoa)항암 chemical structure spider web
방문Thomas MartinMD
Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA(Thomas Martin, MD)은 BCMA 표적 세포·유전자 치료로, Multiple Myeloma; Recurrent Multiple Myeloma 영역에서 개발·상용화 중입니다. 작용기전: CAR T-cell product type, and higher day 0 C-reactive protein were independently associated with lower odds of 72-hour SNI. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 97.1% (ClinicalTrials.gov NCT03548207). 차별점: novel light-controlled immunotherapy strategy that integrates a red/far-red light genetic switch with single-cell encapsulati.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
BCMA
Multiple Myeloma; Recurrent Multiple Myeloma
Discontinued
2026-09-02
Data Confidence · Medium
Development Signal · Watch
CAR T-cell product type, and higher day 0 C-reactive protein were
AAV) but is clinically still in an early developmental stage
humanized mouse models and exhibited retained sensitivity to alternative agents permitting rapid in vivo supp
novel light-controlled immunotherapy strategy that integrates a red/far-red light genetic switch with single-cell encapsulati
CAR T-cell product type, and higher day 0 C-reactive protein were independently associated with lower odds of 72-hour SNI
t cellular production also enable a deep B‑cell or plasma cell depletion via T cell-mediated cytotoxicity
payloads directly into target cells via receptor-mediated internalization
biomarkers such as body composition metrics
escape
구조화 데이터
xenograft model
mouse, mouse, mouse
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Thomas MartinMD
Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA(Thomas Martin, MD)은 BCMA 표적 세포·유전자 치료로, Multiple Myeloma; Recurrent Multiple Myeloma 영역에서 개발·상용화 중입니다. 작용기전: CAR T-cell product type, and higher day 0 C-reactive protein were independently associated with lower odds of 72-hour SNI. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 97.1% (ClinicalTrials.gov NCT03548207). 차별점: novel light-controlled immunotherapy strategy that integrates a red/far-red light genetic switch with single-cell encapsulati.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
BCMA
Multiple Myeloma; Recurrent Multiple Myeloma
Discontinued
2026-09-02
Data Confidence · Medium
Development Signal · Watch
CAR T-cell product type, and higher day 0 C-reactive protein were
AAV) but is clinically still in an early developmental stage
humanized mouse models and exhibited retained sensitivity to alternative agents permitting rapid in vivo supp
novel light-controlled immunotherapy strategy that integrates a red/far-red light genetic switch with single-cell encapsulati
CAR T-cell product type, and higher day 0 C-reactive protein were independently associated with lower odds of 72-hour SNI
t cellular production also enable a deep B‑cell or plasma cell depletion via T cell-mediated cytotoxicity
payloads directly into target cells via receptor-mediated internalization
biomarkers such as body composition metrics
escape
구조화 데이터
xenograft model
mouse, mouse, mouse
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.